Keyhole Limpet Hemocyanin in Chronic Hepatitis C

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study the investigators examine the safety and efficacy of Keyhole-limpet-hemocyanin in patients with chronic hepatitis c infection and liver cirrhosis. The investigators hypothesize that administration of keyhole-limpet-hemocyanin reduces the viral load in patients infected with hepatitis c.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of Graz
• Treatments: Keyhole-limpet hemocyanin

Criteria

Inclusion Criteria:

• Chronic Hepatitis C infection

• no previous therapy

• at least one contraindication to interferon therapy

• liver cirrhosis

• age between 18-80 y

• women of not childbearing age

Exclusion Criteria:

• Hypersensitivity against keyhole-limpet hemocyanin

• previous treatment against hepatitis c

• autoimmune disorders

• immunosuppression

• hepatocellular carcinoma or other malignancies

• coinfection with hepatitis b or HIV

• pregnancy

• cardiovascular event during the last 6 months (stroke or MCI)

• uncontrolled diabetes

• renal insufficiency (GFR < 50 ml/min) or chronic hemodialysis